First-Line Treatment Patterns of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) with and without BRAF Mutations in the US

被引：0
|
作者：
Vieira, M. Cecilia [1 ]
Duncan, K. [1 ]
Hsu, W. -C. [2 ]
Ross, R. [2 ]
Benjumea, D. [2 ]
Vlahiotis, A. [1 ]
Li, B. [1 ]
Wilner, K. D. [3 ]
机构：
[1] Pfizer Inc, New York, NY USA
[2] Genesis Res LLC, Hoboken, NJ USA
[3] Pfizer Inc, San Diego, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP01.61
引用
收藏
页码：E36 / E36
页数：1
相关论文
共 50 条
  • [1] Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
    Martinez, Pablo
    Peters, Solange
    Stammers, Timothy
    Soria, Jean-Charles
    CLINICAL CANCER RESEARCH, 2019, 25 (09) : 2691 - 2698
  • [2] First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly
    Losanno, Tania
    Gridelli, Cesare
    CURRENT ONCOLOGY REPORTS, 2021, 23 (10)
  • [3] First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly
    Tania Losanno
    Cesare Gridelli
    Current Oncology Reports, 2021, 23
  • [4] First-line treatment for non-small cell lung cancer
    Pinn, Stephen
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2011, 72 (01) : 10 - 10
  • [5] Association of early tumor growth rate and survival outcomes in first-line metastatic non-small cell lung cancer (mNSCLC).
    Fojo, Antonio Tito
    Brown, Kevin
    Grootendorst, Diederik J.
    Kotapati, Srividya
    Fronheiser, Matthew
    Tran, Phuong
    Rizzo, Jasmine I.
    Leung, David
    Zhao, Binsheng
    Schwartz, Lawrence Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    Brown, T.
    Boland, A.
    Bagust, A.
    Oyee, J.
    Hockenhull, J.
    Dundar, Y.
    Dickson, R.
    Ramani, V. S.
    Proudlove, C.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 71 - 79
  • [7] Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    Fleeman, N.
    Bagust, A.
    McLeod, C.
    Greenhalgh, J.
    Boland, A.
    Dundar, Y.
    Dickson, R.
    Smith, C. Tudur
    Davis, H.
    Green, J.
    Pearson, M.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 47 - 53
  • [8] First-line combination immunotherapy for metastatic non-small cell lung cancer
    Chen, Yuh-Min
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2020, 83 (05) : 433 - 441
  • [9] First-line treatment of metastatic NSCLC (mNSCLC) patients without actionable mutations in US community oncology clinical practice
    McKay, Caroline
    Arunachalam, Ashwini
    Burke, Thomas A.
    Cao, Xiting
    Abernethy, Amy P.
    Carbone, David Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07)
  • [10] PATIENT CHARACTERISTICS AND FIRST LINE TREATMENTS AMONG MEDICARE PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC)
    Ejzykowicz, F.
    Chen, X.
    Petrilla, A.
    Schroeder, A.
    Dietz, K.
    Agatep, B.
    Burke, T.
    Lopes, G.
    VALUE IN HEALTH, 2020, 23 : S25 - S25
12345